Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. To that end, it has amycretin in FDA phase 1 and CagriSema in phase-2 trials, which both show greater efficacy ...

The current car is offered with two engines – a 1.5-litre turbocharged three-cylinder with mild-hybrid technology and a 2.0-litre turbocharged four-cylinder. We’d like a little more choice ...

All dose strengths, from 0.25 milligrams to 2.4 milligrams, are priced the same. The list price for Wegovy is around $1,350 per month. Novo Nordisk says that 90% of U.S. patients who take Wegovy have ...

The latest results “confirmed the superior efficacy of CagriSema in people with overweight or obesity and type 2 diabetes”, said Martin Holst Lange, Novo Nordisk’s executive vice-president ...

Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial ...

Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...

Shares of Novo Nordisk dropped Monday after the company ... In a late-stage trial of people with obesity and type 2 diabetes, the treatment, called CagriSema, led patients to lose 13.7% of their ...